Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
166
Frequently Asked Questions
What is Market Cap of Zentalis Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Zentalis Pharmaceuticals Inc market cap is $107.48M.
What is the 52-week high for Zentalis Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Zentalis Pharmaceuticals Inc 52 week high is $4.44 as of September 30, 2025.
What is the 52-week low for Zentalis Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Zentalis Pharmaceuticals Inc 52 week low is $1.01 as of September 30, 2025.
What is Zentalis Pharmaceuticals Inc stock price today?
Zentalis Pharmaceuticals Inc stock price today is $1.51.
What was Zentalis Pharmaceuticals Inc stock price yesterday?
Zentalis Pharmaceuticals Inc stock price yesterday was $1.49.
What is the PE ratio of Zentalis Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Zentalis Pharmaceuticals Inc’s P/E ratio is -0.65.
What is the Price-to-Book ratio of Zentalis Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Zentalis Pharmaceuticals Inc P/B ratio is 0.3916.
What is the 50-day moving average of Zentalis Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Zentalis Pharmaceuticals Inc 50-day moving average is $1.55.
How many employess does Zentalis Pharmaceuticals Inc has?
